Oxaprozin
From Wikipedia, the free encyclopedia
 |
|
|
Oxaprozin
|
|
| Systematic (IUPAC) name | |
| 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H15NO3 |
| Mol. mass | 293.317 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 99% |
| Metabolism | Liver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites. |
| Half life | 54.9 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | Oral |
Oxaprozin, also known as Oxaprozinum, (sold under the names: Daypro or Duraprox) is a non-steroidal anti-inflammatory drug (NSAID),[1] used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. It is available in 600 mg tablets. Normal adult dosage is 1200 mg daily, not to exceed 1800 mg per day. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.
[edit] References
- ^ Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI (March 1985). "Oxaprozin pharmacokinetics in the elderly". British journal of clinical pharmacology 19 (3): 373–8. PMID 3986088.
|
|||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
